Simpson Thacher recently represented the underwriters, led by J.P. Morgan, TD Cowen, Jefferies and Stifel, in connection with the registered follow-on offering of 5,750,000 shares of Class A common stock by Nuvalent, Inc. (“Nuvalent”). The offering raised approximately $540.5 million in gross proceeds.
Nuvalent is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
The Simpson Thacher team included John O'Connell, John C. Ericson, Art Robinson, Julie De Keukeleire and Anna Jarman (Capital Markets); Vanessa Burrows and Jacob Madden (Healthcare); Paige Brinton (IP); Drew Purcell and Michael Mann (Tax); Pasco Struhs (ECEB); and Andrew Pagliughi (FINRA and Blue Sky).